Keywords
How to Cite
Abstract
Menopause is the transitioning phase of a woman at the end of her reproductive age and which is associated with both anatomical and physiological changes, with great compromise of quality of life. It is of upmost importance to be aware of the currently available therapeutic options, the evidence that supports them, and thus, be able to provide the best alternative according to medical indications, efficacy, adverse effects and counter-indications. Methods: We conducted a search on the databases Cochrane, Pubmed, SciELO, JAMA, both in English and Spanish, without date restrictions. Conclusion: Current therapies are not satisfactory, either because of their low efficacy in symptom control or because of the associated risks. It is necessary to make a thorough evaluation of the benefit/risk relation for every individualized case.
2. Guyton A, Hall J. Tratado de fisiología médica. 12a ed. Barcelona: Elsevier; 2011.
3. Lethaby A, Ayeleke R, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;(8). doi: https://doi.org/10.1002/14651858.CD001500.pub3.
4. Sturdee DW, Panay N. Recomendaciones para el manejo de la atrofia vaginal postmenopáusica. Int Menopause Soc. 2010;13(6):509-22.
5. Thurston RC, Joffe H. Vasomotor symptoms and menopause: findings from the study of women’s health across the nation. Obstet Gynecol Clin N Am. 2011;38:489-501.
6. Nelson HD, Vesco KK, Haney EE, Fu R, Nedrow A, Miller J, et al. Nonhormonal therapies for menopausal hot flashes, systematic review and meta-analysis. JAMA. 2006;295(17):2057-71.
7. Rincón O, Díaz I, Ernesto LE. Patogénesis de la osteoporosis: papel de los estrógenos. Rev Colomb Obst Ginecol. 2007;58(2):141-9.
8. Goodman NF, Ginzburg SB. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Menopause. Endocr Pract. 2011;17 Suppl 6:1-25.
9. Manson JE, Chiebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women’s health initiative randomized trials. JAMA. 2013;310(13):1353-68.
10. Boardman HMP, Hartley L, Elsinga A, Main C, Roqué I Figuls M, Bonfill Cosp X, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015;(3): doi: https://doi.org/10.1002/14651858.CD002229. pub4.
11. Freedman EW, Guthrie KA, Caan B, Sternfeld B, Cohen LS, Joffe H, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women. JAMA. 2011;305(3):267-74.
12. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes, a randomized controlled trial. JAMA. 2003;289(21):2827-34.
13. Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev. 2013;(12). doi: https://doi.org/10.1002/14651858.CD001395.pub4.
14. The American College of Obstetricians and Gynecologists. The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer [internet]. Mar 2016. Disponible en: https://www.acog.org/-/media/Committee-Opinions/Committee-on-Gynecologic-Practice/co659.pdf?dmc=1&ts=20181024T1335414704.
15. Daley A, Stoker-Lampard H, Thomas A, MacArthur C. Exercise for vasomotor menopausal symptoms. Cochrane Databse Syst Rev. 2014;(11):CD006108. doi: https://doi.org/10.1002/14651858.pub4.
16. Khan A, Fortier M. Osteoporosis in menopause. J Obstet Gynaecol Can [internet]. 2014;36(9 eSuppl C):839-40. Disponible en: https://sogc.org/wp-content/uploads/2014/09/JOGC-Sept2014-CPG-312_Eng_Online-Complete.pdf.
17. Goldstein S. An efficient tool for the primary care management of menopause. Can Fam Physician. 2017 Apr; 63:295-8.
18. Reddish S. Menopause: A treatment algorithm. Aus Fam Phyiscian. 2002 May;31(5):423-4.
19. National Institute for Health and Care Excellence. Menopause: diagnosis and management. NICE guideline NG23; 2015.
This journal is registered under a Creative Commons Attribution 4.0 International Public License. Thus, this work may be reproduced, distributed, and publicly shared in digital format, as long as the names of the authors and Pontificia Universidad Javeriana are acknowledged. Others are allowed to quote, adapt, transform, auto-archive, republish, and create based on this material, for any purpose (even commercial ones), provided the authorship is duly acknowledged, a link to the original work is provided, and it is specified if changes have been made. Pontificia Universidad Javeriana does not hold the rights of published works and the authors are solely responsible for the contents of their works; they keep the moral, intellectual, privacy, and publicity rights.
Approving the intervention of the work (review, copy-editing, translation, layout) and the following outreach, are granted through an use license and not through an assignment of rights. This means the journal and Pontificia Universidad Javeriana cannot be held responsible for any ethical malpractice by the authors. As a consequence of the protection granted by the use license, the journal is not required to publish recantations or modify information already published, unless the errata stems from the editorial management process. Publishing contents in this journal does not generate royalties for contributors.